BBHC
ALXN

Brown Brothers Harriman & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-207
Closed -$38 – 1250
2021
Q2 		$38 Sell
207
-50
-19% -$8.58K ﹤0.01% 718
2021
Q1 		$39 Buy
257
+10
+4% +$1.55K ﹤0.01% 684
2020
Q4 		$39K Buy
247
+207
+518% +$26.6K ﹤0.01% 701
2020
Q3 		$5K Hold
40
– – ﹤0.01% 833
2020
Q2 		$4K Buy
40
+5
+14% +$531 ﹤0.01% 858
2020
Q1 		$3K Sell
35
-293
-89% -$28.8K ﹤0.01% 902
2019
Q4 		$35K Sell
328
-872
-73% -$93.3K ﹤0.01% 725
2019
Q3 		$118K Hold
1,200
– – ﹤0.01% 518
2019
Q2 		$157K Buy
1,200
+1,127
+1,544% +$145K ﹤0.01% 434
2019
Q1 		$10K Buy
+73
New +$9.08K ﹤0.01% 846
2018
Q3 		– Sell
-100
Closed -$12K – 912
2018
Q2 		$12K Sell
100
-175
-64% -$20.5K ﹤0.01% 647
2018
Q1 		$31K Buy
275
+50
+22% +$5.98K ﹤0.01% 524
2017
Q4 		$27K Buy
+225
New +$27.4K ﹤0.01% 604
2017
Q2 		– Sell
-72
Closed -$9K – 837
2017
Q1 		$9K Sell
72
-278
-79% -$35.8K ﹤0.01% 674
2016
Q4 		$43K Buy
+350
New +$42.8K ﹤0.01% 508
2016
Q3 		– Sell
-6
Closed -$1K – 840
2016
Q2 		$1K Hold
6
– – ﹤0.01% 816
2016
Q1 		$1K Sell
6
-176
-97% -$25.8K ﹤0.01% 668
2015
Q4 		$35K Sell
182
-17
-9% -$2.97K ﹤0.01% 502
2015
Q3 		$31K Buy
199
+21
+12% +$3.83K ﹤0.01% 553
2015
Q2 		$32K Hold
178
– – ﹤0.01% 549
2015
Q1 		$31K Buy
178
+50
+39% +$9.05K ﹤0.01% 561
2014
Q4 		$24K Buy
+128
New +$23.7K ﹤0.01% 617
2014
Q2 		– Sell
-21
Closed -$3K – 828
2014
Q1 		$3K Buy
+21
New +$3.34K ﹤0.01% 741
2013
Q4 		– Sell
-17
Closed -$2K – 721
2013
Q3 		$2K Buy
+17
New +$1.86K ﹤0.01% 663

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Brown Brothers Harriman & Co's ALXN Position: Q3 2021 in Review

Brown Brothers Harriman & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 207 shares — an estimated $38 sold.

Brown Brothers Harriman & Co first reported a position in ALXN in Q3 2013 and held it in 24 quarters. The position peaked at $157K in Q2 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Brown Brothers Harriman & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 207 Alexion Pharmaceuticals shares in Q3 2021, an estimated $38.
  • Brown Brothers Harriman & Co first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 24 quarters.
  • Brown Brothers Harriman & Co's Alexion Pharmaceuticals position peaked at $157K in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2021, filed 15 Nov 2021.